Learning Method and Medium

This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.

Content Source

This continuing medical education (CME) activity captures content from a roundtable discussion held on April 25, 2014, in Boston, Massachusetts.

Activity Description

Recently, much attention in ophthalmic surgery has revolved around technology. Current medical literature suggests that the foundations of inflammation and infection management are key factors in achieving positive outcomes across the spectrum of ophthalmic surgical procedures using new technologies. In this educational activity, a panel of expert anterior segment and glaucoma surgeons discuss the changing landscape of perioperative planning for ocular surgery, using a framework of patient cases to serve as examples of the challenges faced in achieving successful ophthalmic surgery.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

Upon completion of this activity, ophthalmologists will be better able to:

• Recall data on ocular antibiotic resistance patterns
• Identify effective antibiotics for patients undergoing ophthalmic procedures
• Demonstrate the use of evidence-based inflammation-control regimens for patients undergoing cataract surgery, LASIK, and corneal transplant surgery
• Identify optimal preoperative inflammation control practice
• Recall data from clinical trials on the efficacy and safety of new anti-inflammatory agents used in cataract surgery
• Select optimal anti-inflammatory agents while considering efficacy and IOP control for patients undergoing glaucoma surgery

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providorship of New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC. The New York Eye and Ear Infirmary of Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.

In July 2013, the Accreditation Council for Continuing Medical Education (ACCME) awarded New York Eye and Ear Infirmary of Mount Sinai “Accreditation with Commendation,” for six years as a provider of continuing medical education for physicians, the highest accreditation status awarded by the ACCME.

AMA Credit Designation Statement

The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grantor Statement

This continuing medical education activity is supported through an unrestricted educational grant from Bausch + Lomb Incorporated.

Disclosure Policy Statement

It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). New York Eye and Ear Infirmary of Mount Sinai has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

Disclosures

Douglas A. Katsev, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees/Advisory Boards: Bausch + Lomb Incorporated; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureau); Abbott Medical Optics; Alcon, Inc; Allergan, Inc; and Bausch + Lomb Incorporated.

Terrence P. O’Brien, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees/Advisory Boards: Alcon, Inc; Bausch + Lomb Incorporated; Santen Pharmaceutical Co, Ltd; and Senju Pharmaceutical Co, Ltd.

John Sheppard, MD, MMSc, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees/Advisory Boards: Abbvie Inc; Alcon, Inc; Allergan, Inc; Bausch + Lomb Incorporated; Doctor’s Allergy Formula; Imprimis Pharmaceuticals, Inc; Merck & Co, Inc; Omeros Corporation; ScienceBased Health; Tearlab Corporation; and TearScience; Contracted Research: Alcon, Inc; Bausch + Lomb Incorporated; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureau); Alcon, Inc; and Bausch + Lomb Incorporated.

Rohit Varma, MD, MPH, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees/Advisory Boards: Allergan, Inc.

New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure

Joseph Panarelli, MD, has no financial relationships to disclose.

Editorial Support Disclosures

Cynthia Tornallyay, RD, MBA, CCMEP; Kimberly Corbin, CCMEP; Barbara Aubel; and Barbara Lyon have no relevant commercial relationships to disclose.

Tony Realini, MD (Writer), had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consulting Fees/Advisory Boards: Alcon, Inc; Contracted Research: Lumenis Ltd.

Disclosure Attestation

The contributing physicians listed above have attested to the following:

1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
2) that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

Off-Label Discussion
This activity discusses unapproved use of cefuroxime. Please refer to the official prescribing information for discussion of approved indications, contraindications, and warnings.

For Digital Editions
System Requirements:
If you are viewing this activity online, please ensure the computer you are using meets the following requirements:
- Operating System: Windows or Macintosh
- Media Viewing Requirements: Flash Player or Adobe Reader
- Supported Browsers: Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
- A good internet connection

New York Eye and Ear Infirmary of Mount Sinai
Privacy & Confidentiality Policies
CME policies: http://www.nyee.edu/cme-enduring.html
Hospital policies: http://www.nyee.edu/website-privacy.html

CME Provider Contact Information
For questions about this activity, call 212-979-4383.

To Obtain AMA PRA Category 1 Credit™
To obtain AMA PRA Category 1 Credit™ for this activity, read the material in its entirety and consult referenced sources as necessary. Complete the evaluation form along with the post test answer box within this supplement. Remove the Activity Evaluation/Credit Request page from the printed supplement or print the Activity Evaluation/Credit Request page from the Digital Edition. Return via mail to Kim Corbin, Director, ICME, New York Eye and Ear Infirmary of Mount Sinai, 310 East 14th Street, New York, NY 10003 or fax to (212) 353-5703. Your certificate will be mailed to the address you provide on the Activity Evaluation/Credit Request form. Please allow 3 weeks for Activity Evaluation/Credit Request forms to be processed. There are no fees for participating in and receiving CME credit for this activity. Alternatively, we offer instant certificate processing and support Green CME. Please take this post test and evaluation online by going to http://tinyurl.com/CMEfoundationsCME. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Bausch + Lomb Incorporated, or EyeNet Magazine.

Photos for Figures 1 through 9 Courtesy of Terrance P. O’Brien, MD

---

**Introduction**

Ocular surgery is a major event in many people’s lives, and in some cases—particularly cataract or corneal transplant surgery—can be a life-changing event as well. We all hope our technical skills to ensure a safe and effective procedure, and technological advances continue to raise the bar of what is possible to achieve with clinical outcomes. As an example, consider the evolution of intraocular lenses (IOLs). We have seen the progression from early monofocal designs, in which biocompatibility was a principal concern, to multifocal, accommodating, and advanced toric IOLs with improved optical performance, such that we can now provide better postoperative visual function with cataract surgery than ever before. As a result, patients’ expectations are changing and ascending. Many patients know someone who has undergone successful cataract surgery and therefore expect the same or better results for themselves. To ensure realization of optimal outcomes to meet these increasing expectations, we must put as much thought into our perioperative interventions as we invest in the surgical procedure itself. Postoperative inflammation can be painful and can jeopardize visual outcomes. The worst-case scenario—a severe infection such as endophthalmitis—is, thankfully, very rare, but for the unlucky patient who does suffer an intraocular infection, the outcome is often devastating. In this educational activity, we have assembled a panel of expert anterior segment and glaucoma surgeons to discuss the changing landscape of perioperative planning for ocular surgery, using a framework of patient cases that we have encountered in our own practices to serve as examples of the challenges we all face in achieving successful ophthalmic surgery.

Our goals are to underscore the need to reconsider older strategies that have stood the test of time and to provide insight into the adoption of newer strategies to secure the best postoperative visual and overall outcomes for our patients.

—Terrence P. O’Brien, MD

**Case 1. Infection and Inflammation Prophylaxis in a High-Risk Patient**

**Dr O’Brien:** A 61-year-old woman with a history of inflammatory bowel disease began, in her late 30s, to have anterior uveitis with recurrent episodes of iridocyclitis. She had been controlled with chronic topical corticosteroids and now has developed a painless progressive deterioration in vision with increasing lenticular opacification. She also has significant posterior synechiae with a 3.0-mm pupil that is minimally reactive to light [Figure 1]. She now presents for consideration of cataract surgery. How do we approach this patient case?

**Dr Sheppard:** This is clearly a patient who requires meticulous preparation prior to surgery. First and foremost, we want to be sure that her systemic disease is under control. If she has Crohn disease or ulcerative colitis, direct collaboration with her gastroenterologist or rheumatologist is necessary to assure that the systemic disease is under control. Following confirmation that any inflammatory bowel disease is under control—ideally achieved with minimal use of systemic steroids—we likewise need to minimize ocular inflammation. It is imperative that we have zero tolerance for inflammation in the eye: no cell, no flare, no superficial punctate keratopathy, and if possible, no cystoid macular edema [Figure 2], although this may be difficult to assess in a small-pupil cataract patient.

---

![Figure 1.](image1.png)

---

![Figure 2.](image2.png)
Once these conditions have been met, we can proceed to the operating room. There we pre-treat with higher and more frequent doses of anti-inflammotory agents, and in cases such as this, it is often worth giving a perioperative or preoperative sub-Tenon steroid injection. Factors that support a sub-Tenon steroid injection in this patient are her high risk for reactivating the underlying inflammation, the likelihood of an impaired blood-aqueous barrier promoting greater inflammation, and the certainty of extensive iris manipulation intraoperatively to break the extensive posterior synechia. She also may benefit from intracameral use of preservative-free steroids; both dexamethasone and triamcinolone are available for this use. The IOL selection is important in this patient. I favor a higher-order hydrophobic IOL material, and clearly, in-the-bag placement is crucial.

Postoperative inflammation control is critically important. We want a potent steroid, such as difluprednate or loteprednol, along with a concomitant nonsteroidal anti-inflammatory drug (NSAID). Patients such as the one we are discussing should be watched very carefully postoperatively. We often see a toxic anterior segment syndrome (TASS)-like picture on day 1 with prolific fibrin in the anterior chamber [Figure 3] and a great deal of cells and flare, which can promote secondary posterior synechia to the capsule.

**Figure 3.**

Dr O’Brien: Preoperatively, this patient also requires frequent pulses of topical corticosteroids for control of her ocular inflammation as well as a topical beta-blocker and carbonic anhydrase inhibitor (CAI) for control of intraocular pressure (IOP). In addition to the posterior synechia mentioned, gonioscopy disclosed peripheral anterior synechia with heavy pigment in the trabecular meshwork and a narrowing of the angle. She has been noted more recently to have borderline control of IOP on the current regimen. Dr Varma, do you have any suggestions for the cataract or glaucoma surgeon approaching cataract surgery in this complicated patient?

Dr Varma: With long-term use of IOP-lowering drugs, there is a whole series of inflammatory responses that occur in the conjunctiva secondary to either the preservative in the medication or to the medication itself. This inflammatory component in the conjunctiva reduces the chances of success of glaucoma surgery in the future and will also have bearing on the more imminent cataract surgery. Fortunately, recent studies have shown that cataract surgery alone can result in an effective IOP-lowering for many patients.1,2 Postoperatively, this patient’s IOP may be easier to control, potentially on fewer medications. Complicating this, however, is her need for aggressive inflammation suppression, which may require high-potency steroids that may raise her IOP. In her case, loteprednol may be preferable to difluprednate because of its relatively lesser effect on IOP than that of other steroids.3,4 The trade-off may be an attendant lesser effect on inflammation, so these 2 situations would have to be monitored. On balance, inflammation is likely to cause more damage than transient elevated IOP. I would tend to be more aggressive with inflammation control, even if the IOP rises, and then taper as quickly as possible to restore IOP control.

Dr O’Brien: In general, when in the perioperative period should we start anti-inflammatory therapy?

Dr Katsev: I pre-treat all my patients 2 to 3 days before surgery with both the antibiotic and the anti-inflammatory agents—both the steroid and the nonsteroidal drugs. I favor pretreatment to get inflammation under control before it starts. I do this in all my patients, but in the case we are discussing now, pretreatment for inflammation is of utmost importance.5

Dr O’Brien: I agree that pretreatment with anti-inflammatory agents is rational. Suppression of key enzymes such as cyclooxygenase can deplete the downstream supply of inflammatory mediators such as prostaglandins, leukotrienes, prostacyclins, and thromboxanes. If we wait and allow unchecked conversion of metabolites of arachidonic acid to feed into the cycle, “the horse is already out of the barn” with respect to ocular inflammation. What is the optimal approach to the miotic, mechanically bound pupil in this case?

Dr Katsev: In this case, you first have to get the pupil open. Viscodilation can be effective in many cases and would be the best place to start because it is the least traumatic of the available approaches.

Dr O’Brien: I agree completely with trying the gentler viscodissection/viscodilation approach first. More aggressive pupil manipulation intraoperatively to break the extensive posterior synechia with heavy pigment in the trabecular meshwork and a narrowing of the angle. She has been noted more recently to have borderline control of IOP on the current regimen. Dr Varma, do you have any suggestions for the cataract or glaucoma surgeon approaching cataract surgery in this complicated patient?

Dr Varma: With long-term use of IOP-lowering drugs, there is a whole series of inflammatory responses that occur in the conjunctiva secondary to either the preservative in the medication or to the medication itself. This inflammatory component in the conjunctiva reduces the chances of success of glaucoma surgery in the future and will also have bearing on the more imminent cataract surgery. Fortunately, recent studies have shown that cataract surgery alone can result in an effective IOP-lowering for many patients.1,2 Postoperatively, this patient’s IOP may be easier to control, potentially on fewer medications. Complicating this, however, is her need for aggressive inflammation suppression, which may require high-potency steroids that may raise her IOP. In her case, loteprednol may be preferable to difluprednate because of its relatively lesser effect on IOP than that of other steroids.3,4 The trade-off may be an attendant lesser effect on inflammation, so these 2 situations would have to be monitored. On balance, inflammation is likely to cause more damage than transient elevated IOP. I would tend to be more aggressive with inflammation control, even if the IOP rises, and then taper as quickly as possible to restore IOP control.

Dr O’Brien: In general, when in the perioperative period should we start anti-inflammatory therapy?

Dr Katsev: I pre-treat all my patients 2 to 3 days before surgery with both the antibiotic and the anti-inflammatory agents—both the steroid and the nonsteroidal drugs. I favor pretreatment to get inflammation under control before it starts. I do this in all my patients, but in the case we are discussing now, pretreatment for inflammation is of utmost importance.5

Dr O’Brien: I agree that pretreatment with anti-inflammatory agents is rational. Suppression of key enzymes such as cyclooxygenase can deplete the downstream supply of inflammatory mediators such as prostaglandins, leukotrienes, prostacyclins, and thromboxanes. If we wait and allow unchecked conversion of metabolites of arachidonic acid to feed into the cycle, “the horse is already out of the barn” with respect to ocular inflammation. What is the optimal approach to the miotic, mechanically bound pupil in this case?

Dr Katsev: In this case, you first have to get the pupil open. Viscodilation can be effective in many cases and would be the best place to start because it is the least traumatic of the available approaches.

Dr O’Brien: I agree completely with trying the gentler viscodissection/viscodilation approach first. More aggressive pupil manipulation intraoperatively to break the extensive posterior synechia with heavy pigment in the trabecular meshwork and a narrowing of the angle. She has been noted more recently to have borderline control of IOP on the current regimen. Dr Varma, do you have any suggestions for the cataract or glaucoma surgeon approaching cataract surgery in this complicated patient?

Dr Varma: With long-term use of IOP-lowering drugs, there is a whole series of inflammatory responses that occur in the conjunctiva secondary to either the preservative in the medication or to the medication itself. This inflammatory component in the conjunctiva reduces the chances of success of glaucoma surgery in the future and will also have bearing on the more imminent cataract surgery. Fortunately, recent studies have shown that cataract surgery alone can result in an effective IOP-lowering for many patients.1,2 Postoperatively, this patient’s IOP may be easier to control, potentially on fewer medications. Complicating this, however, is her need for aggressive inflammation suppression, which may require high-potency steroids that may raise her IOP. In her case, loteprednol may be preferable to difluprednate because of its relatively lesser effect on IOP than that of other steroids.3,4 The trade-off may be an attendant lesser effect on inflammation, so these 2 situations would have to be monitored. On balance, inflammation is likely to cause more damage than transient elevated IOP. I would tend to be more aggressive with inflammation control, even if the IOP rises, and then taper as quickly as possible to restore IOP control.

Dr O’Brien: In general, when in the perioperative period should we start anti-inflammatory therapy?

Dr Katsev: I pre-treat all my patients 2 to 3 days before surgery with both the antibiotic and the anti-inflammatory agents—both the steroid and the nonsteroidal drugs. I favor pretreatment to get inflammation under control before it starts. I do this in all my patients, but in the case we are discussing now, pretreatment for inflammation is of utmost importance.5

Dr O’Brien: I agree that pretreatment with anti-inflammatory agents is rational. Suppression of key enzymes such as cyclooxygenase can deplete the downstream supply of inflammatory mediators such as prostaglandins, leukotrienes, prostacyclins, and thromboxanes. If we wait and allow unchecked conversion of metabolites of arachidonic acid to feed into the cycle, “the horse is already out of the barn” with respect to ocular inflammation. What is the optimal approach to the miotic, mechanically bound pupil in this case?

Dr Katsev: In this case, you first have to get the pupil open. Viscodilation can be effective in many cases and would be the best place to start because it is the least traumatic of the available approaches.

Dr O’Brien: I agree completely with trying the gentler viscodissection/viscodilation approach first. More aggressive pupil manipulation intraoperatively to break the extensive posterior synechia with heavy pigment in the trabecular meshwork and a narrowing of the angle. She has been noted more recently to have borderline control of IOP on the current regimen. Dr Varma, do you have any suggestions for the cataract or glaucoma surgeon approaching cataract surgery in this complicated patient?

Dr Varma: With long-term use of IOP-lowering drugs, there is a whole series of inflammatory responses that occur in the conjunctiva secondary to either the preservative in the medication or to the medication itself. This inflammatory component in the conjunctiva reduces the chances of success of glaucoma surgery in the future and will also have bearing on the more imminent cataract surgery. Fortunately, recent studies have shown that cataract surgery alone can result in an effective IOP-lowering for many patients.1,2 Postoperatively, this patient’s IOP may be easier to control, potentially on fewer medications. Complicating this, however, is her need for aggressive inflammation suppression, which may require high-potency steroids that may raise her IOP. In her case, loteprednol may be preferable to difluprednate because of its relatively lesser effect on IOP than that of other steroids.3,4 The trade-off may be an attendant lesser effect on inflammation, so these 2 situations would have to be monitored. On balance, inflammation is likely to cause more damage than transient elevated IOP. I would tend to be more aggressive with inflammation control, even if the IOP rises, and then taper as quickly as possible to restore IOP control.

Dr O’Brien: In general, when in the perioperative period should we start anti-inflammatory therapy?

Dr Katsev: I pre-treat all my patients 2 to 3 days before surgery with both the antibiotic and the anti-inflammatory agents—both the steroid and the nonsteroidal drugs. I favor pretreatment to get inflammation under control before it starts. I do this in all my patients, but in the case we are discussing now, pretreatment for inflammation is of utmost importance.5
Universal adoption of the ESCRS protocol is happening gradually. I use it currently in all high-risk cases—for example, in patients presenting with capsular rupture and vitreous prolapse, in immunocompromised patients such as those who have had organ transplants, in younger patients, in those with a history of prior eye trauma, and in patients with diabetes. In Europe, there is a commercially prepared formulation of cefuroxime available as a single-dose unit specifically meant for intracameral use. In the United States, we are compounding systemic doses, which come with small but real risks. When we have a formulation of cefuroxime in this country that eliminates those risks, I will adopt its use as a universal practice for all my patients.

Dr O’Brien: What are the antimicrobial activity gaps in the spectrum of coverage with cefuroxime and other limitations with this particular antibacterial agent?

Dr Sheppard: The possibility of dilutional errors during preparation are a concern. Also, cefuroxime is an older antibiotic and may have some resistance issues. However, given the high concentration injected directly into the anterior chamber, relative resistance may be overcome. One other issue with the delivery method is that of aqueous fluid ingress—potentially carrying bacteria—is the bigger turnover time. Is the antibiotic cleared too quickly? This is particularly relevant if there is any wound leak, which could cause faster loss of the drug. For this reason, topical antibiotics are still necessary in the postoperative period.

Dr O’Brien: Will the use of biocompatible adhesive agents at the conclusion of surgery help to seal cataract wounds more effectively and safely?

Dr Sheppard: Absolutely. Antibiotic egress from an incompetent wound is only 1 side of the coin. Surface fluid ingress—potentially carrying bacteria—is the bigger issue. These adhesive agents tend to last several days postoperatively and to provide improved comfort as well as less risk of contamination. With that improved comfort, there is less eye-rubbing, and thereby a dual beneficial effect.

Case 2. Infection Prophylaxis in a MRSA-Colonized Patient

Dr O’Brien: A 59-year-old retired female nurse has hyperopia and is interested in refractive surgery to correct her visual acuity. She has minimal cataract, corrects to 20/20, and is considering LASIK (laser-assisted in situ keratomileusis) surgery. She is a known carrier of MRSA. How would you approach this patient case?

Dr Sheppard: For this patient, whether she is about to undergo cataract extraction, corneal transplantation, or a glaucoma procedure, the surgeon should first obtain a preoperative ocular surface culture with sensitivities. Although nasal carriers do not necessarily also grow MRSA in the ocular flora, vigilance is indicated. If the resistant organisms proliferate and the patient’s ocular flora has been changed about by our previous antibiotic treatment. Then, when this patient presents for cataract surgery, he or she may have an altered profile and increased endophthalmitis risk brought about by our previous antibiotic treatment.

Dr. Katsev: I would be less aggressive with this patient, not because it is wrong to be too cautious, but rather because my clinical experience has not led me to fear MRSA carriers. I would not get a preoperative culture. I would use my standard pre-LASIK routine, which includes a combination steroid/antibiotic for convenience. In this case, I would use a separate antibiotic with known activity against MRSA, such as besifloxacin; besifloxacin is formulated for ophthalmic use only. Because it is not being used systemically, the risks for overuse and misuse—which can lead to higher resistance rates—are fewer.

Dr. O’Brien: Given how high colonization rates with MRSA are, even in patients presenting for routine outpatient cataract surgery (see Sidebar: Antibiotic Resistance and the Growing Threat of MRSA), having the most robust routine approach to effective prophylaxis against these increasingly prevalent subpopulations of resistant bacteria is wise.

Dr. Sheppard: I agree that routine preoperative cultures are not productive. In patients with known MRSA infection, however, we must pay serious attention to prophylaxis. Health care workers were considered among the highest risk for resistant staphylococcal carriage, but the rise in community-acquired MRSA incidence has heightened our concern for virtually everyone undergoing elective invasive ocular surgery.

Dr. O’Brien: Following LASIK, this patient may present with a partially hazy cornea in the early postoperative period. How can we clinically differentiate diffuse lamellar keratitis (DLK) from infectious keratitis following LASIK?

Dr. Sheppard: Diffuse lamellar keratitis, the infamous Sands of the Sahara syndrome, is a relatively common phenomenon, much more common than infectious interface keratitis (Figure 5). In DLK, the eyes are hot and inflamed. You can see very fine micropunctate white blood cells that do not look like an infiltrate. They are very discrete, as opposed to a homogenous migratory infiltrate most likely at the edge of the flap with infection. The patient with DLK complains more of blurring and ache than of outright pain and photophobia as do patients with infectious interface keratitis. Diffuse lamellar keratitis tends to occur immediately postoperatively and is very responsive to topical steroids (Figure 6). There is a nearly 6-fold increased risk of DLK in patients with untreated allergic and atopic disease, and this risk essentially vanishes with treatment. Evaluating the risk factors and examining the character of the interface phase is very important.

Case 3. Prophylaxis for Glaucoma Surgery

Dr. O’Brien: An 81-year-old woman has a history of primary open-angle glaucoma and has required multiple agents over an expanse of 20 years to control her IOP. Currently, she requires maximal medical therapy consisting of latanoprost, brimonidine, and a beta-blocker/CAI fixed combination. She also has undergone selective laser trabeculoplasty, with minimal effect on lowering IOP. She is now being considered as a candidate for glaucoma filtering surgery. On preoperative evaluation, she is noted to have moderate meibomian gland inspissation (Figure 7), a rapid tear film break-up time, and punctate staining of the interpalpebral corneal epithelium. How do you approach this patient who is being considered for elective glaucoma surgery?

Dr. Varma: This patient’s ocular surface disease (OSD) includes both dry eye and blepharitis, which together increase the risk for postoperative infection. We have to address and control these issues before we proceed to surgery. One likely contributor to her OSD is the chronic use of IOP-lowering medications. It has been well established that chronic exposure to topical glaucoma drugs incites a chronic low-grade inflammation in the conjunctiva, which can diminish the success of subsequent glaucoma surgery. For this reason, I would strongly consider a preoperative course of topical steroid therapy to suppress the inflammation. In addition to OSD, other risk factors for postoperative bleb infection or frank endophthalmitis are the use of antifibrotic agents such as mitomycin-C or 5-fluorouracil, younger patient age, and inferior bleb placement in the setting of superior scarring. Is it the pressure-lowering agents themselves or the preservatives in their formulations—notably benzalkonium
chloride—that are the culprits in this induced inflammation on the surface of the eye?

Dr Varma: Benzalkonium chloride has significant cytotoxic effects on the human ocular surface and on the cells that make up this layer.\textsuperscript{18-21} Even though subtle conjunctival inflammation may not be clinically apparent, a 4- to 6-week course of topical anti-inflammatory therapy is wise. Loteprednol is a reasonable choice, or fluorometholone if available, because it has potent steroid activity but is less likely to raise IOP compared with prednisolone acetate.\textsuperscript{3,4} Additional benefits of preoperative anti-inflammatory therapy—in this case with ketorolac or fluorometholone—are that it may improve the success of trabeculectomy and reduce the need for postoperative needling of Tenon cysts.\textsuperscript{22}

Dr O’Brien: Is there a role for noncorticosteroid agents such as topical and/or systemic immunomodulators in controlling the OSD prior to surgery?

Dr Sheppard: Cyclosporine, 0.05%, emulsion is an effective nonsteroidal anti-inflammatory agent. It is formulated for ophthalmic use and labeled for the treatment of dry eye syndrome. There are also systemic drugs—the tetracyclines doxycycline and minocycline, in particular—that are effective in managing OSD. An initial high dose followed by chronic low-dose therapy can provide excellent maintenance well below the typical dosage needed to achieve antimicrobial activity.\textsuperscript{23}

Dr O’Brien: Usually we try to avoid systemic IOP-lowering medications, especially in those of advancing age, because of the adverse reaction profile associated with CAIs. In this type of patient, is there a role for temporarily replacing the topical agents with a systemic agent during the preoperative period while simultaneously initiating the anti-inflammatory pulse to better control ocular surface inflammation?

Dr Varma: This can be a worthwhile consideration. In this patient, however, because of her age (81 years old), the risks associated with systemic CAI therapy may be unacceptable. These risks include numbness and tingling of the extremities, increased urination, depression, development of kidney stones, and in very rare cases, aplastic anemia. If she declines surgery and is willing to accept these risks, a trial of systemic CAI therapy may not be unreasonable. Another option would be a trial of preservative-free IOP-lowering medications to attempt to quiet her eye.

Dr O’Brien: The tear film is the single greatest defense against ocular surface infections. In the postoperative glaucoma patient, the filtering bleb, or the glaucoma drainage device, alters the way the eyelid moves across the ocular surface. This can alter the ocular surface itself, change the tear flow across the surface, and lead to problems with preoperative biometry if cataract surgery follows. Also, the use of antimetabolites can further increase the risk for postoperative infection. Which organisms should we be most concerned about as potential causes of infection in eyes following glaucoma surgery?

Dr Varma: The 2 main forms of postoperative infection in eyes having undergone glaucoma procedures are blebitis and endophthalmitis. Blebitis is limited to infection within the subconjunctival bleb, although some spillover of cells may be seen in the anterior chamber [Figure 8].

Dr O’Brien: Prompt attention is essential. What is your current preferred topical approach for blebitis with the goal of preventing endophthalmitis?

Dr Varma: I want to emphasize the importance of culturing the bleb area or the vitreous before beginning anti-infective therapy for blebitis or endophthalmitis, respectively. For blebitis, I prescribe an advanced-generation fluoroquinolone as frequently as every hour initially. I will taper the frequency according to the response.

Dr Sheppard: When I see blebitis accompanied by even a few cells in the anterior chamber, I will use fortified vancomycin. I may also use subconjunctival aminoglycoside therapy, such as gentamicin. I also follow a patient with blebitis very closely, perhaps twice a day for the first day or 2, to be sure the blebitis is not progressing to endophthalmitis.

Dr O’Brien: Consider the patient now 4 years after trabeculectomy with adjunctive mitomycin-C who currently presents with visually significant cataract. The bleb is intact, but very thin-walled and cystic in appearance. What would be your approach to infection prophylaxis in the perioperative period?

Dr Varma: I would examine very carefully, including Seidel testing, to be absolutely sure that the bleb is intact and that there is no low-grade blebitis present. Operating on an eye with a low-grade...
Managing Generic Substitutions

Dr Katsev: It is not uncommon for me to prescribe the antibiotic of my choice only to receive a phone call from the pharmacy asking if it can substitute a less expensive agent because my preferred drug is not covered by the patient’s insurance. I am often surprised by this as the cost saving for the generic medication can be very minimal in actual dollar amount. Dealing with this is time consuming, and use of the substituted agent can be potentially dangerous. In the perioperative period surrounding intraocular surgery, I want to use the very best agent I can, with the most favorable susceptibility profile. The use of electronic health records can facilitate matters somewhat by showing me what is and is not covered on a patient-by-patient basis when I e-prescribe. Then at least I know which patients may or may not receive optimal prophylaxis.

Dr Varma: In the glaucoma practice, substitution of IOP-lowering medications can be a benign and cost-saving event, or it can become a safety issue. Some of the so-called generic medications are produced overseas and are, in fact, not generic—that is, they are not equivalent in formulation to the branded product. They may contain different concentrations of the drug, be less heat stable, and may have higher levels of contaminants such as particulate matter in the bottles. We strongly discourage the use of generics that have been prepared outside the United States.

Dr Sheppard: Another issue with generics is that their availability changes regularly. Each time a pharmacy renegotiates contracts, it goes with the lowest bidder, and that means the formulation of NSAID you are prescribing for, for example, may be produced by a different manufacturer with a different vehicle and preservative every few months. If there is significant variability in the activity and stability of these formulations, we are faced with a new variable in our surgical protocol over which we have little control.

Dr O’Brien: How can ophthalmic surgeons manage this issue so that our surgical patients are provided with differentiated, preferred pharmaceutical agents of our own choosing?

Dr Sheppard: One option is to adopt a business model that includes an in-house pharmacy, to provide complete control of all these variables. In today’s regulatory environment, however, to do this can be overly burdensome. In my practice, we make our recommendations for the particular antibiotic, steroid, or NSAID agents that we prefer the patient to use; we have a disclosure document that patients sign as part of their cataract documentation, acknowledging that they understand we are recommending this specific regimen and that we advise against substitution. The substituted drugs may have more side effects, less efficacy, and need to be dosed more frequently. In the event a patient cannot afford our preferred regimen, it is prudent we do our research and have prepared, as a backup plan, a specified list of generic alternatives, so that we can at least ensure that the patient gets our preferred generic choice rather than one chosen at random by the pharmacy.

I am a firm believer in a high-quality, low dosing-frequency regimen. It improves compliance, it improves efficacy, and it reduces exposure to toxic preservatives. This huge benefit is available only through proprietary topical preparations.1

Dr O’Brien: Should we be concerned about the potential added infectious risk associated with the corneal donor tissue being harvested, processed, and maintained in corneal preservation/storage media?

Dr Katsev: Unfortunately, acute corneal hydrops is a fairly typical presentation in these eyes with keratoconus [Figure 10]. Atopy is associated with keratoconus, and controlling the itching will minimize the eye-rubbing and slow or prevent progression. It is too late to prevent this outcome in the right eye, but corneal crosslinking may help reduce a similar risk in the fellow eye. In terms of perioperative prophylaxis, the first step is to control the atopy and the itching. Systemic steroids may be needed to accomplish this. This patient may also require an allergy consult with allergy testing, desensitization, and even immunotherapy. In terms of ocular anti-inflammatory agents, I would start with a high-potency steroid such as topical difluprednate or subconjunctival triamcinolone and then transition to a safer steroid such as loteprednol, which is less likely to raise IOP, for lifelong maintenance. Atopy also poses an infection risk, especially if there is associated blepharitis and, often, a history of chalazia as well. If this is the case, a preoperative lid culture is valuable to identify the resistance patterns of the patient’s flora.

Dr Sheppard: Culturing the media from a donor does not make as much sense to me as culturing the actual donor rim. The media contains, among other things, streptomycin and gentamicin at low concentrations, which preclude a highly positive culture rate; therefore, we get a great deal of false-negatives when culturing the media. I just culture the rim now. Many times it grows *Strep. epidermidis*. But, the patients do well. I am generally only greatly concerned when the rim culture grows a fungus. I will bring those patients back to the office for a careful examination. I have had a case of Descemet stripping endothelial keratoplasty in which the rim culture grew fungus and the patient—who had chronic lymphocytic leukemia and thus was immunocompromised—developed a fungal endophthalmitis and lost the eye.

Dr O’Brien: Assuming the transplant is successful and the graft is clear, how do you prevent rejection over time in this 39-year-old phakic patient?

Dr Sheppard: All my transplant patients, without fail, receive lifelong latreprednol. It is my maintenance antirejection agent of choice. This is the best anti-inflammatory agent for long-term use because of its safety and efficacy profile. I titrate the dose according to the risk profile of the patient, considering factors such as age, previous rejections, and concomitant inflammatory ocular surface or intraocular disease. These are high-risk factors for graft failure. In some cases we can reduce the steroid dose with a steroid-sparing agent such as cyclosporine if the patient has dry eye and if the agent’s use is justified, given the added expense.

**Summary and Conclusion**

Dr O’Brien: As we strive to strengthen the foundation for successful anterior segment surgery through careful perioperative planning and prophylaxis (Table), let us each share 1 pearl that guides our clinical and/or surgical decision-making.

Dr Varma: Surgeons should look carefully at the ocular surface and the lid prior to embarking on any filtration surgery and address any issues preoperatively. Doing so will have a huge effect on the outcome, in terms of reducing both inflammation and the postoperative risk for infection.

Dr Katsev: Start your preoperative medications early—not just a day before, but consider a couple of days before. Quelling inflammation will control OSD, reduce abrasion, and optimize IOL calculations. We also should choose the most effective antibiotic we can in terms of minimal resistance among the bacteria about which we are most concerned.

Dr Sheppard: Each patient is different. Each patient needs a specific customized approach to his or her diagnosis and therapy. We are fortunate that so many options continue to be developed to help us individualize patient care.

Dr O’Brien: Infection matters. Resistance is important in ophthalmology. Epidemiologic surveillance of ocular pathogens continues to demonstrate the importance of steering our attention to bacterial resistance, prompting us to alter our strategies to prevent infection from occurring during ophthalmic surgeries. Inflammation also matters: inflammation can lower the success rate of our otherwise technologically advanced ophthalmic procedures. Delaying surgery to address OSD preoperatively may seem inconvenient, but often is prudent to gain the most accurate input data and to avoid potentially devastating complications postoperatively.

### Table. New Agents for Perioperative Prophylaxis

Several agents have been developed recently in the ocular anti-infective and anti-inflammatory categories and their salient features are summarized below.

#### Anti-Infective Agents

- **Besifloxacin**
  - Fluroquinolone formulated specifically for ocular use
  - Active against ocular pathologic isolates, including MRSA, that are resistant to other antibiotics

- **Gatifloxacin, 0.5%**
  - Reformulation at higher dose (was 0.3%)

#### Anti-Inflammatory Agents

- **Bromfenac, 0.07%**
  - Reformulation at lower dose (was 0.1%) with once-daily dosing
  - Effective in suppressing postoperative inflammation and pain following cataract surgery dosed once daily in 2 RCTs

- **Nepafenac, 0.3%**
  - Reformulation at higher dose to achieve qd dosing (was 0.1% tid)
  - Effective in suppressing postoperative inflammation and pain following cataract surgery in RCT
  - Also indicated in Europe for diabetic macular edema prevention in those with diabetes undergoing cataract surgery

- **Loteprednol, 0.5%**
  - Reformulation (was a suspension)
  - Corticosteroid designed to be less apt than prednisolone acetate to raise IOP
  - Effective in suppressing postoperative inflammation and pain following cataract surgery dosed once daily in 2 RCTs

- **Difluprednate, 0.05%, emulsion**
  - Patent corticosteroid
  - Emulsion, so no shaking required
  - Prodrug activated after ocular penetration
  - Higher risk for elevated IOP than occurs with other steroids

RCTs=randomized clinical trials.


References


Post Test

To obtain AMA PRA Category 1 Credit™ for this activity, complete the CME Post Test by writing the best answer to each question in the Answer Box located on the Activity Evaluation/Credit Request form on the following page. Alternatively, you can complete the CME Post Test online at http://tinyurl.com/FoundationsCME.

See detailed instructions at To Obtain AMA PRA Category 1 Credit™ on page 3.

1. In patients with preexisting OSD, which of the following would be the least desirable method of controlling inflammation in the perioperative period for cataract surgery?
   a. Intracameral steroids
   b. Topical steroids
   c. Systemic steroids
   d. Sub-Tenon steroids

2. Which of the following is/are an advantage(s) of preoperative anti-inflammatory therapy before cataract surgery?
   a. Reduction of postoperative inflammation by reducing precursors to inflammation
   b. Less intraoperative miosis
   c. Less aberrant biometry for lens power calculation
   d. All the above

3. As shown in the ESCRS study, to what extent did the use of intracameral cefuroxime at the end of each cataract surgery procedure reduce the risk for endophthalmitis?
   a. 2-fold
   b. 5-fold
   c. 8-fold
   d. 12-fold

4. Which of the following is false regarding MRSA?
   a. The prevalence of MRSA is increasing over time
   b. Early-generation fluoroquinolones are highly effective against MRSA
   c. Approximately 15% of cataract patients are colonized with S aureus, of which approximately one-third are MRSA
   d. MRSA is the leading cause of post-LASIK infections

5. Diffuse lamellar keratitis and infectious interface keratitis can appear similar. Which of the following is true regarding methods to distinguish between these 2 entities?
   a. In inflammatory keratitis, there is typically anterior chamber cell and flare
   b. In infectious keratitis, very fine and discrete micropunctate white blood cells can be seen
   c. Pain, photophobia, and anterior chamber cell suggest infection rather than noninfectious inflammatory DLK
   d. None of the above is true

6. Which of the following is false regarding glaucoma and perioperative infection?
   a. Topical IOP-lowering medications can cause conjunctival inflammation
   b. Preservatives such as benzalkonium chloride promote inflammation
   c. Preoperative topical steroids should be avoided because of the risk for IOP elevation
   d. Conjunctival inflammation can reduce glaucoma surgery success

7. The most common organisms responsible for acute infections following glaucoma surgery are:
   a. S aureus and H influenzae
   b. S pneumoniae and S aureus
   c. S aureus and S epidermidis
   d. H influenzae and Enterococcus species

8. In a patient with allergic or atopic disease facing intraocular surgery, which of the following is true?
   a. Reducing inflammation is necessary to prevent itching and eye-rubbing postoperatively
   b. Systemic steroid therapy may be needed, and an allergy consultation may be of value
   c. Atopy increases the risk for postoperative infection 6-fold
   d. All the above are true

9. Which of the following is false regarding the use of prophylactic antibiotics and resistance?
   a. The primary cause of resistance is antibiotic overuse
   b. The majority of antibiotic use in the United States is within the food production industry
   c. Topical prophylactic antibiotic use during intravitreal injections does not lead to antibiotic resistance
   d. None of the above is false

10. Which of the following best characterizes similarities between branded products and their generic formulations?
    a. Same active ingredients
    b. Same inactive ingredients
    c. Same active and inactive ingredients
    d. Same stability to heat
Activity Evaluation/Credit Request

Building Foundations for Successful Ophthalmic Surgery

To receive AMA PRA Category 1 Credits™, you must complete this Evaluation form and the Post Test. Record your answers to the Post Test in the Answer Box located below. Mail or Fax this completed page to New York Eye and Ear Infirmary of Mount Sinai—ICME, 310 East 14th Street, New York, NY 10003 (Fax: 212-353-5703). Your comments help us to determine the extent to which this educational activity has met its stated objectives, assess future educational needs, and create timely and pertinent future activities. Please provide all the requested information below. This ensures that your certificate is filled out correctly and is mailed to the proper address. It also enables us to contact you about future CME activities. Please print clearly or type. Illegible submissions cannot be processed.

PARTICIPANT INFORMATION

(Please Print) ☐ Home ☐ Office

Last Name ____________________________ First Name ____________________________

Specialty ____________________________ Degree ☑ MD ☑ DO ☑ OD ☑ PharmD ☑ RPh ☑ NP ☑ RN ☑ PA ☑ Other ____________________________

Institution ____________________________

City ____________________________ State ____________________________ ZIP Code ____________________________ Country ____________________________

E-mail ____________________________ Phone ____________________________ Fax ____________________________

Please note: We do not sell or share e-mail addresses. They are used strictly for conducting post-activity follow-up surveys to assess the impact of this educational activity on your practice.

Learner Disclosure: To ensure compliance with the US Centers for Medicare and Medicaid Services regarding gifts to physicians, New York Eye and Ear Infirmary of Mount Sinai Institute for CME requires that you disclose whether or not you have any financial, referral, and/or other relationship with our institution. CME certificates cannot be awarded unless you answer this question. For additional information, please call NYEE ICME at 212-979-4383. Thank you.

☐ Yes ☐ No 1 and/or my family member have a financial relationship with New York Eye and Ear Infirmary of Mount Sinai and/or refer Medicare/Medicaid patients to it.

☐ I certify that I have participated in the entire activity and claim 1.5 AMA PRA Category 1 Credits™.

Signature Required ____________________________ Date Completed ____________________________

OUTCOMES MEASUREMENT

☐ Yes ☐ No Did you perceive any commercial bias in any part of this activity? IMPORTANT! If you answered “Yes,” we urge you to be specific about where the bias occurred so we can address the perceived bias with the contributor and/or in the subject matter in future activities.

Circle the number that best reflects your opinion on the degree to which the following learning objectives were met:

5 = Strongly Agree 4 = Agree 3 = Neutral 2 = Disagree 1 = Strongly Disagree

Upon completion of this activity, I am better able to:

• Recall data from ocular antibiotic resistance patterns 5 4 3 2 1
• Identify effective antibiotics for patients undergoing ophthalmic procedures 5 4 3 2 1
• Demonstrate use of evidence-based inflammation-control regimens for patients undergoing cataract surgery, LASIK, and corneal transplant surgery 5 4 3 2 1
• Identify optimal preoperative inflammation control practice 5 4 3 2 1
• Recall data from clinical trials on the efficacy and safety of new anti-inflammatory agents used in cataract surgery 5 4 3 2 1
• Select optimal anti-inflammatory agents while considering efficacy and IOP control for patients undergoing glaucoma surgery 5 4 3 2 1

1. Please list one or more things, if any, you learned from participating in this educational activity that you did not already know:

_________________________________________________________________________________________________________________________________

2. As a result of the knowledge gained in this educational activity, how likely are you to implement changes in your practice?

4=definitely will implement changes 3=likely will implement changes 2=likely will not implement any changes 1=definitely will not make any changes

_________________________________________________________________________________________________________________________________

3. Related to what you learned in this activity, what barriers to implementing these changes or achieving better patient outcomes do you face?

_________________________________________________________________________________________________________________________________

4. Please check the Core Competencies (as defined by the Accreditation Council for Graduate Medical Education) that were enhanced for you through participation in this activity. ☑ Patient Care ☑ Practice-Based Learning and Improvement ☑ Professionalism ☑ Medical Knowledge ☑ Interpersonal and Communication Skills ☑ Systems-Based Practice

5. What other topics would you like to see covered in future CME programs?

_________________________________________________________________________________________________________________________________

ADDITIONAL COMMENTS

_________________________________________________________________________________________________________________________________

POST TEST ANSWER BOX

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
</table>